Ignite Creation Date:
2025-12-24 @ 10:49 PM
Ignite Modification Date:
2025-12-31 @ 9:45 AM
Study NCT ID:
NCT02657369
Status:
TERMINATED
Last Update Posted:
2019-10-15
First Post:
2016-01-13
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
Sponsor:
Eisai Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-07-07
Start Date Type:
ACTUAL
Primary Completion Date:
2018-09-26
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-09-26
Completion Date Type:
ACTUAL
First Submit Date:
2016-01-13
First Submit QC Date:
None
Study First Post Date:
2016-01-15
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2019-09-25
Results First Submit QC Date:
None
Results First Post Date:
2019-10-15
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-09-25
Last Update Post Date:
2019-10-15
Last Update Post Date Type:
ACTUAL